Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials.
Fiche publication
Date publication
février 2023
Journal
International journal of cardiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Ferreira JP, Cleland JG, Girerd N, Rossignol P, Pellicori P, Cosmi F, Mariottoni B, González A, Diez J, Solomon SD, Claggett B, Pfeffer MA, Pitt B, Petutschnigg J, Pieske B, Edelmann F, Zannad F
Lien Pubmed
Résumé
Spironolactone might improve the prognosis of patients with heart failure with preserved left ventricular ejection fraction (HFpEF), but the mechanisms by which it acts are uncertain. Serum concentrations of procollagen type I carboxy-terminal propeptide (PICP) reflect the synthesis of type I collagen and correlate well with histologically proven cardiac fibrosis.
Mots clés
Anti-fibrotic therapy, Fibrosis, HFpEF, Spironolactone
Référence
Int J Cardiol. 2023 02 2;: